Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

Example Input: Context: Francesco Gessi (20 January 1588 -- 1649) was an Italian painter of the Baroque period, active mainly in Bologna. 
 Question: In what city did Francesco Gessi die?
Example Output: bologna

Example Input: Context: Future Life Pets By DogTown Media, LLC Open iTunes to buy and download apps. *Price: $2.99 *Category: Lifestyle *Updated: Jan 07, 2012 *Version: 1.1 *Size: 36.3 MB *Language: English *Seller: DOG TOWN MEDIA *(c) DogTown Media LLC Description DISCOVER FUTURE LIFETIMES WITH YOUR PETS You can be transported into the future to be reunited with your pet in another place and time. As an internationally recognized psychic and best-selling author, Anne Jirsch will be your guide in this fascinating meditation game. Future Life Pets will take you into a state of deep relaxation to help you understand this special condition. With expert hypnosis you can discover how your paths will cross in your future lifetime. WHAT PEOPLE ARE SAYING "I immediately saw I was riding a tall black and white horse and you've guessed it --it was my dog and this time he was bigger than ever." --Mike from Kansas City. "Seeing both my cats in the future lifetime has given me so much joy. They are both cats again next time around, only a lot bigger and smoother. I clearly saw them both lie by my feet just as they do right now." --Felicity from Manchester, UK. The regular buyers of Anne's products include heads of industry, politicians, and celebrities of all kinds. She is a world famous psychic and author of three books Instant Intuition, The Future is Yours, and Cosmic Energy. More than a billion people in the world believe in the truth of meditation, through which we'll gain a greater understanding of our pets and ourselves. Prepare for the experience as the results are astonishing. 
 Question: If we want to use the app of Future Life Pets, what kind of language should we know?
Example Output: english

Example Input: Context: The Philadelphia chromosome found in leukemia cells of chronic myelogenous leukemia (CML) patients is produced by translocation between chromosomes 9 and 22, resulting in expression of a chimera protein of Bcr and Abl kinase in the cytoplasm. Bcr-Abl kinase attracted oncology researchers as a molecular target for CML therapy, and a variety of small Abl kinase inhibitors were synthesized. STI571 (imatinib mesylate) was produced by modification of 2-phenylaminopyrimidine, a core structure of protein kinase C inhibitor, to improve selectivity, stability, solubility, and bioavailability. STI571 competitively binds to the ATP binding site of Bcr-Abl kinase and inhibits Abl tyrosine kinase activity. STI571 showed significant efficacy in the clinical study with CML patients at all stages: chronic phase, accelerated phase, and blast crisis. More than 90% of the patients showed good hematologic response to STI571. STI571 is also a potent inhibitor of a receptor-type c-Kit tyrosine kinase. Therefore, STI571 was examined for therapeutic efficacy against malignant Gastro-Intestinal Stromal Tumors (GIST), which are mainly caused by aberrant expression of a mutated c-Kit that is constitutively active without binding of a ligand, stem cell factor (SCF). More than a half of the metastatic GIST patients enrolled in the clinical study responded to STI571. Thus, STI571 is now used as a therapeutic drug for both CML and GIST in more than 80 countries worldwide. Certain point mutations in the ATP binding site were found to be a cause of resistance to STI571 in both Bcr-Abl and c-Kit kinases. Therefore, it would be better to make a precise therapeutic strategy with STI571 based on the gene analysis data. It is also expected that it will be possible to design an inhibitor to overcome such resistance by using the structural information on the mutants. 
 Question: What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?
Example Output:
bcr-abl